From Economic Time
MUMBAI: Global pharma companies have now increased the amount of outsourced clinical research — a critical part of new drug development — to emerging economies, and clinical trials done in India have grown massively.

A large pool of naive patients (that have not been exposed to too many medicines), a larger spectrum of disease profiles and a genetically distinct group are proving to be trump cards for India. According to a publication by the US National Institute of Health, the number of clinical trials conducted in India has more than doubled in just over a year.

As the number of clinical trials coming to India increases, the safety of patients participating in them is becoming a growing concern. Guidelines are in place for pharma companies conducting clinical research in India, ensuring that they are always followed has proven difficult.

Read More...